BlackRock Health Sciences Trust (BME) Annual Income Statement (USD)
BME Quarterly Financials (USD)
Frequently Asked Questions About BlackRock Health Sciences Trust (BME) Stock
BlackRock Health Sciences Trust's (BME) last reported annual revenue was USD 8.19 Million.
BlackRock Health Sciences Trust's (BME) annual revenue growth rate based on the revenue reported in the past 5 years is : -18.57%
BlackRock Health Sciences Trust's(BME) is profitable as of its last reported annual financials.
The net profit margin for BlackRock Health Sciences Trust's(BME) from its laster reported year is 244.30%
The return on equity (ROE) for BlackRock Health Sciences Trust's(BME) from its last reported annual financials is : 9.01%
The return on assets (ROA) for BlackRock Health Sciences Trust's(BME) from its last reported annual financials is : 0.17%
The return on invested capital (ROIC) for BlackRock Health Sciences Trust's(BME) from its last reported annual financials is : 0.00%
The Debt to Equity ratio for BlackRock Health Sciences Trust's(BME) from its last reported annual financials is : 0.00%
The dividend yield for BlackRock Health Sciences Trust's(BME) from its laster reported year is 8.40%
BlackRock Health Sciences Trust's(BME) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BME !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
